Metabolism and excretion of canagliflozin in mice, rats, dogs, and humanss

Drug Metabolism and Disposition

Volumn 42, Issue 5, 2014, Pages 903-916

  Mamidi, Rao N V S ^a   Cuyckens, Filip ^b   Chen, Jie ^b   Scheers, Ellen ^b   Kalamaridis, Dennis ^b   Lin, Ronghui ^b   Silva, Jose ^b   Sha, Sue ^a   Evans, David C ^b   Kelley, Michael F ^b   Devineni, Damayanthi ^a   Johnson, Mark D ^a   Lim, Heng Keang ^b  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; CANAGLIFLOZIN C 14; CARBON 14; CAS 842133 18 0; DRUG METABOLITE; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; CARBON; GLUCOSIDE; GLUCURONIDE; THIOPHENE DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ARTICLE; BILE DUCT; CONTROLLED STUDY; DETOXIFICATION; DOG; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG OXIDATION; DRUG SAFETY; DRUG SOLUBILITY; DRUG TRANSFORMATION; FECES; FEMALE; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; RAT; SINGLE DRUG DOSE; ANIMAL; BILE; BLOOD; CHEMISTRY; CLINICAL TRIAL; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ORAL DRUG ADMINISTRATION; SPECIES DIFFERENCE; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION; URINE; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; ANIMALS; BILE; CARBON RADIOISOTOPES; DOGS; FECES; FEMALE; GLUCOSIDES; GLUCURONIDES; HUMANS; HYPOGLYCEMIC AGENTS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MIDDLE AGED; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; THIOPHENES; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 84898821701     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.056440     Document Type: Article

References (17)

1. Beumer JH, Beijnen JH, and Schellens JH (2006) Mass balance studies, with a focus on anticancer drugs. Clin Pharmacokinet 45:33-58.
2. Chen L, Magliano DJ, and Zimmet PZ (2012) The worldwide epidemiology of type 2 diabetes mellitus-present and future perspectives. Nat Rev Endocrinol 8:228-236.
3. Cuyckens F, Koppen V, Kembuegler R, and Leclercq L (2008) Improved liquid chromatography: online radioactivity detection for metabolite profiling. J Chromatogr A 1209:128-135.
4. Devineni D, Curtin CR, Polidori D, Gutierrez MJ, Murphy J, Rusch S, and Rothenberg PL (2013) Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J Clin Pharmacol 53:601-610.
5. Gao H, Jacobs A, White RE, Booth BP, and Obach RS (2013) Meeting report: metabolites in safety testing (MIST) symposium-safety assessment of human metabolites: what's REALLY necessary to ascertain exposure coverage in safety tests? AAPS J 15:970-973.
6. Hamilton RA, Garnett WR, and Kline BJ (1981) Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther 29:408-413.
7. Hardman TC and Dubrey SW (2011) Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes. Diabetes Ther 2:133-145.
8. Institute of Laboratory Animal Resources(1996) Guide for the Care and Use of Laboratory Animals, 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
9. Liang Y, Arakawa K, Ueta K, Matsushita Y, Kuriyama C, Martin T, Du F, Liu Y, Xu J, and Conway B, et al. (2012) Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS ONE 7:e30555.
10. Lim HK, Chen J, Sensenhauser C, Cook K, Preston R, Thomas T, Shook B, Jackson PF, Rassnick S, and Rhodes K,, et al. (2011) Overcoming the genotoxicity of a pyrrolidine substituted arylindenopyrimidine as a potent dual adenosine A(2A)/A(1) antagonist by minimizing bioactivation to an iminium ion reactive intermediate. Chem Res Toxicol 24:1012-1030.
11. Lim HK, Chen J, Sensenhauser C, Cook K, and Subrahmanyam V (2007) Metabolite identification by data-dependent accurate mass spectrometric analysis at resolving power of 60,000 in external calibration mode using an LTQ/Orbitrap. Rapid Commun Mass Spectrom 21:1821-1832.
12. Nomura S, Sakamaki S, Hongu M, Kawanishi E, Koga Y, Sakamoto T, Yamamoto Y, Ueta K, Kimata H, and Nakayama K, et al. (2010) Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J Med Chem 53:6355-6360.
13. Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, Usiskin K, Capuano G, and Canovatchel W; Canagliflozin DIA 2001 Study Group (2012) Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 35:1232-1238.
14. Sha S, Devineni D, Ghosh A, Polidori D, Chien S, Wexler D, Shalayda K, Demarest K, and Rothenberg P (2011) Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 13:669-672.
15. Stark Casagrande S, Fradkin JE, Saydah SH, Rust KF, and Cowie CC (2013) The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010. Diabetes Care 36:2271-2279.
16. Verbruggen A, Coenen HH, Deverre JR, Guilloteau D, Langstrom B, Salvadori PA, and Halldin C (2008) Guideline to regulations for radiopharmaceuticals in early phase clinical trials in the EU. Eur J Nucl Med Mol Imaging 35:2144-2151.
17. Wright EM, Hirayama BA, and Loo DF (2007) Active sugar transport in health and disease. J Intern Med 261:32-43.